Clinical trials: Rosuvastatin
Primary Hypercholesterolemia
Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting
This study assessed the safety and efficacy of generic Rosuvastatin in reducing plasma low density lipoprotein (LDL) cholesterol in Lebanese adult patients (18 years or older) with dyslipidemia for both primary and secondary…
- Trial name
- NCT03516955
- Testing
- Rosuvastatin
- Volunteers
- 317 people
- Sponsor
- Hikma Pharmaceuticals LLC
RSV Infection, Drug Drug Interaction
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
The primary aim of this study is to assess the effect of EDP-323 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy adult participants.
- Trial name
- NCT06917508
- Testing
- EDP-323, Midazolam, Caffeine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Hypercholesterolemia
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).
- Trial name
- NCT01730040
- Testing
- Alirocumab, Atorvastatin, Ezetimibe
- Where
- 97 sites in United States, Australia and 7 more
- Volunteers
- 355 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes Mellitus, Type 2
Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin
study effects of rosuvastatin on markers of atherosclerosis, thrombosis, in diabetic patients treated with glimepiride/metformin without coronary artery disease. This effect will be investigated especially on sortilin ,fetuin-A
- Trial name
- NCT03907423
- Testing
- Rosuvastatin10 mg tablet
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Rehab Werida
Dyslipidemias
A Study to Evaluate the Efficacy and Safety of CREZET Tablet
This observation study is to evaluate blood lipid-lowering effects and liver/renal safety, changes in HbA1c and FPG in patients with dyslipidemia who administered CREZET tablets for 24 weeks.
- Trial name
- NCT05889143
- Testing
- Ezetimibe/Rosuvastatin
- Where
- South Korea
- Volunteers
- 15,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Cardiovascular Diseases, Cerebrovascular Disease
RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)
The clinical efficacy of LDL-lowering therapy have been proven with strong evidences and more emphasized. However, there are also growing concerns that high-intensity statin would be related to increased risk of adverse effects.
- Conditions
- Cardiovascular Diseases, Cerebrovascular Disease, Peripheral Atherosclerotic Disease
- Trial name
- NCT03044665
- Testing
- Rosuvastatin, Rosuvastatin plus ezetimibe
- Where
- South Korea
- Volunteers
- 3,780 people
- Sponsor
- Yonsei University
cMET-dysregulated Advanced Solid Tumors
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
- Trial name
- NCT02626234
- Testing
- INC280, digoxin, rosuvastatin
- Where
- 15 sites in United States, Austria and 6 more
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteer
A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
This is a multiple part, multiple cohort study evaluating single and multiple ascending doses, relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.
- Trial name
- NCT06717269
- Testing
- NX-5948, Esomeprazole, Famotidine
- Where
- 2 sites in United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Nurix Therapeutics, Inc.
Cirrhosis, Portal Hypertension
Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension
Patients with hepatic cirrhosis and previous variceal bleeding will be randomly assigned to use propranolol or carvedilol. After 8 weeks, rosuvastatin or placebo will be blindly added to nonresponders (HVPG measurement > 12mmHg)…
- Conditions
- Cirrhosis, Portal Hypertension, Variceal Hemorrhage
- Trial name
- Betastatin (NCT03720067)
- Testing
- Propranolol, Carvedilol, Rosuvastatin
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Intracranial Arterial Diseases
Rosuvastatin Treatment for Intracranial Arterial Stenosis Based on Magnetic Resonance Angiography
The purpose of this study is to investigate the effects of rosuvastatin treatment on degree of intracranial arterial stenosis.
- Trial name
- NCT02341794
- Testing
- Rosuvastatin
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Tokyo Medical University
Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC
The purpose of this study is to determine the recommended phase II dose (RP2D) of rosuvastatin that can be given in combination with standard erlotinib treatment in patients with advanced incurable squamous cell cancer and NSCLC.
- Trial name
- NCT00966472
- Testing
- Erlotinib + Rosuvastatin
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Ottawa Hospital Research Institute
Coronary Heart Disease
Statin for Depression in Patients Undergoing Coronary Artery Bypass Graft
Depression is frequently observed in patients with coronary heart disease (CHD) and represents a significant risk factor for major cardiovascular events.
- Trial name
- Stress CABG (NCT01624857)
- Testing
- Rosuvastatin
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Center for Cardiovascular Diseases
Healthy
A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study on a Olostar Tab Versus Two Co-administered Reference Products Olmesartan Medoxomil and Rosuvastatin Calcium in Healthy Volunteers
To demonstrate the bioequivalence of a Olostar Tab versus two co-administered reference IMPs Olmetec and Crestor.
- Trial name
- NCT02561884
- Testing
- Olostar Tab., Co-administration of Olmetec and Crestor
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Dyslipidemia, Acute Coronary Syndromes
Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
This is a 3-month, randomized, parallel-group study with 2 periods, comparing the efficacy and the safety of rosuvastatin 20 mg versus atorvastatin 80 mg in patients with an acute coronary syndrome (ACS).
- Trial name
- NCT00665834
- Testing
- rosuvastatin, atorvastatin
- Where
- 2 sites in Canada
- Volunteers
- 18 people
- Sponsor
- Queen's University
Drug Interactions
Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation
The purpose of this study is to identify and validate a probe cocktail for use in future drug-drug interaction studies. Cytochrome P450 enzymes and transport proteins play important roles in the disposition of drugs.
- Trial name
- NCT00964106
- Testing
- Caffeine, Rosiglitazone, Flurbiprofen
- Where
- 2 sites in South Korea
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dyslipidemias, Hypertension
Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia
This study is to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension patient with Dyslipidemia
- Trial name
- CORONA (NCT03951207)
- Testing
- Rosuampin 10/5mg, Rosuampin 20/5mg, Amlodipine/Atorvastatin 5/20mg
- Where
- South Korea
- Volunteers
- 259 people
- Sponsor
- Yuhan Corporation
Healthy
A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.
An Open-label, Multiple-dose, Fixed-sequence, 3-Period Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions between HGP0904, HGP0608 and HCP1306 in Healthy Male Subjects
- Trial name
- NCT04081844
- Testing
- HCP1306, HGP0904, HGP0608
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Stroke, Intracranial Atherosclerosis
Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis
Purpose: Intracranial atherosclerosis is a common condition in Korean population consisting over 25% of ischemic stroke etiology.
- Trial name
- STAMINA-MRI (NCT02458755)
- Testing
- High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Samsung Medical Center
Dyslipidemias
Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea
A Cohort Study for Comparison of Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration and Statin Prescription Patterns in Patients With Dyslipidemia in Korea.
- Trial name
- NCT04829149
- Testing
- Observational
- Where
- South Korea
- Volunteers
- 5,717 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Postbariatric Hypoglycemia
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses and Drug Drug Interaction of MBX 1416 in healthy volunteers This study includes 3 parts.
- Trial name
- NCT06036784
- Testing
- MBX 1416 (Part A), MBX 1416 (Part B), MBX 1416 (Part C)
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- MBX Biosciences